Working... Menu

Ocular Allergy Treatment Practical Impact Trial ((OAT-PIT))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01808768
Recruitment Status : Unknown
Verified March 2013 by Jayesh G. Kanuga, M.D., Starx Research Center, LLC.
Recruitment status was:  Recruiting
First Posted : March 11, 2013
Last Update Posted : May 30, 2013
Information provided by (Responsible Party):
Jayesh G. Kanuga, M.D., Starx Research Center, LLC

Brief Summary:
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Condition or disease Intervention/treatment Phase
Allergic Conjunctivitis Rhinoconjunctivitis Drug: Alcaftadine Phase 4

Detailed Description:
To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)
Study Start Date : April 2013
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
Drug Information available for: Alcaftadine

Arm Intervention/treatment
Experimental: Alcaftadine
subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
Drug: Alcaftadine
Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
Other Name: Lastacaft

Primary Outcome Measures :
  1. Quality of Life- Eye Allergy Patient Impact Questionnaire [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Ocular Surface Disease Index Pollen Count correlation of symptoms [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens
  2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.
  3. have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.
  4. Are willing/able to follow instructions from the study investigator and his/her study staff.
  5. Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.


Exclusion Criteria:

  1. Active ocular infection;
  2. History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
  3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.
  4. History of unstable, or uncontrolled disease of any nature.
  5. Pregnancy or lactation;
  6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01808768

Layout table for location contacts
Contact: Jayesh Kanuga, MD 732-906-1747
Contact: Erika Julca, LPN,CRC 732-906-1747

Layout table for location information
United States, New Jersey
STARx Research Center Recruiting
Edison, New Jersey, United States, 08820
Contact: Erika Julca, lpn,crc    732-906-1747   
Contact: June Pepe, lpn, ccrc    973-912-9817   
Principal Investigator: Jayesh Kanuga, MD         
Sub-Investigator: Ligaya Centeno, MD         
Sub-Investigator: Ruby Reyes, MD         
Sub-Investigator: Leonard Bielory, MD         
STARx Recruiting
Springfield, New Jersey, United States, 07081
Contact: Leonard Bielory, MD    973-912-9817   
Sub-Investigator: Leonard Bielory, MD         
Sponsors and Collaborators
Starx Research Center, LLC
Layout table for investigator information
Principal Investigator: Jayesh Kanuga, MD Starx Research Center, LLC

Layout table for additonal information
Responsible Party: Jayesh G. Kanuga, M.D., Medical Doctor, Starx Research Center, LLC Identifier: NCT01808768     History of Changes
Other Study ID Numbers: ID IIT- 000373
First Posted: March 11, 2013    Key Record Dates
Last Update Posted: May 30, 2013
Last Verified: March 2013

Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs